These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 28410272)

  • 1. Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis.
    Albaladejo P; Samama CM; Sié P; Kauffmann S; Mémier V; Suchon P; Viallon A; David JS; Gruel Y; Bellamy L; de Maistre E; Romegoux P; Thoret S; Pernod G; Bosson JL;
    Anesthesiology; 2017 Jul; 127(1):111-120. PubMed ID: 28410272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
    Antovic A; Norberg EM; Berndtsson M; Rasmuson A; Malmström RE; Skeppholm M; Antovic J
    Thromb Haemost; 2017 Aug; 117(9):1700-1704. PubMed ID: 28640321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment.
    McGrail R; Revsholm J; Nissen PH; Grove EL; Hvas AM
    Thromb Res; 2016 Dec; 148():107-110. PubMed ID: 27835819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lupus-anticoagulant testing at NOAC trough levels.
    Ratzinger F; Lang M; Belik S; Jilma-Stohlawetz P; Schmetterer KG; Haslacher H; Perkmann T; Quehenberger P
    Thromb Haemost; 2016 Aug; 116(2):235-40. PubMed ID: 27075441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of urgent invasive procedures in patients treated with direct oral anticoagulants: An observational registry analysis.
    Godon A; Gabin M; Levy JH; Huet O; Chapalain X; David JS; Tacquard C; Sattler L; Minville V; Mémier V; Blanié A; Godet T; Leone M; De Maistre E; Gruel Y; Roullet S; Vermorel C; Samama CM; Bosson JL; Albaladejo P;
    Thromb Res; 2022 Aug; 216():106-112. PubMed ID: 35785621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study.
    Vedovati MC; Mosconi MG; Isidori F; Agnelli G; Becattini C
    J Thromb Thrombolysis; 2020 Feb; 49(2):251-258. PubMed ID: 31520364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 8. Are Screening Tests Reliable to Rule Out Direct Oral Anticoagulant Plasma Levels at Various Thresholds (30, 50, or 100 ng/mL) in Emergency Situations?
    Jabet A; Stepanian A; Golmard JL; Flaujac C; Joly BS; Gouin-Thibault I; Siguret V
    Chest; 2018 Jan; 153(1):288-290. PubMed ID: 29307427
    [No Abstract]   [Full Text] [Related]  

  • 9. Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.
    Baldelli S; Cattaneo D; Pignatelli P; Perrone V; Pastori D; Radice S; Violi F; Clementi E
    Bioanalysis; 2016 Feb; 8(4):275-83. PubMed ID: 26808218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry.
    Testa S; Ageno W; Antonucci E; Morandini R; Beyer-Westendorf J; Paciaroni M; Righini M; Sivera P; Verhamme P; Pengo V; Poli D; Palareti G
    Intern Emerg Med; 2018 Oct; 13(7):1051-1058. PubMed ID: 29790125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
    Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
    Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monitoring options and reversal agents for oral anticoagulants].
    Thorup SB; Husted SE; Vang ML
    Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry.
    Blaich C; Müller C; Michels G; Wiesen MH
    Clin Chem Lab Med; 2015 Nov; 53(12):1981-90. PubMed ID: 25901716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
    Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
    Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
    Lagoutte-Renosi J; Le Poupon J; Girard A; Montange D; Davani S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():43-49. PubMed ID: 30292948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.